Aspiriant LLC’s Gilead Sciences GILD Stock Holding History

Aspiriant LLC’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-9,516	Closed	-$602K	–	212
2020 Q3	$602K	Buy	+9,516	New	+$660K	0.05%	141
2020 Q2	–	Sell	-2,786	Closed	-$209K	–	186
2020 Q1	$209K	Buy	+2,786	New	+$193K	0.02%	176
2019 Q3	–	Sell	-3,592	Closed	-$241K	–	220
2019 Q2	$241K	Sell	3,592 -59	-2%	-$3.88K	0.02%	200
2019 Q1	$236K	Sell	3,651 -203	-5%	-$13.5K	0.02%	204
2018 Q4	$241K	Buy	3,854 +326	+9%	+$22.8K	0.02%	206
2018 Q3	$272K	Sell	3,528 -879	-20%	-$66.4K	0.02%	205
2018 Q2	$312K	Sell	4,407 -2,590	-37%	-$183K	0.03%	199
2018 Q1	$527K	Buy	+6,997	New	+$556K	0.05%	150
2017 Q4	–	Sell	-4,418	Closed	-$358K	–	115
2017 Q3	$358K	Buy	4,418 +524	+13%	+$40.1K	0.03%	153
2017 Q2	$276K	Buy	3,894 +950	+32%	+$63.2K	0.02%	177
2017 Q1	$201K	Buy	+2,944	New	+$207K	0.02%	202

Other funds holding GILD

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Aspiriant LLC's GILD Position: Q4 2020 in Review

Aspiriant LLC sold out of Gilead Sciences (GILD) in Q4 2020, closing a stake of 9,516 shares — an estimated $602K sold.

Aspiriant LLC first reported a position in GILD in Q1 2017 and held it in 11 quarters. The position peaked at $602K in Q3 2020. 1,563 funds tracked by Wall St. Rank hold GILD as of Q4 2020.

Aspiriant LLC reported no remaining Gilead Sciences position as of Q4 2020 after selling out during the quarter.
Aspiriant LLC sold 9,516 Gilead Sciences shares in Q4 2020, an estimated $602K.
Aspiriant LLC first reported a position in Gilead Sciences in Q1 2017 and held it in 11 quarters.
Aspiriant LLC's Gilead Sciences position peaked at $602K in Q3 2020.
1,563 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2020.

Based on Aspiriant LLC's 13F filing for Q4 2020, filed 1 Feb 2021.